Build Your Own Blood Test

A 2C-B urine test is a qualitative screening that detects the presence of 2C-B (4-bromo-2,5-dimethoxyphenethylamine) or its metabolites in urine. 2C-B is a synthetic psychedelic phenethylamine with stimulant and hallucinogenic properties.

A 3-MMC urine test is a qualitative screening that detects the presence of 3-methylmethcathinone (3-MMC) or its metabolites in urine. 3-MMC is a synthetic cathinone with stimulant and empathogenic properties.

A 6-MAM urine test is a qualitative screening that detects the presence of 6-monoacetylmorphine (6-MAM) in urine. 6-MAM is a unique metabolite of heroin (diacetylmorphine) and its presence confirms heroin exposure specifically, rather than general opiate use.

An EtG urine test is a qualitative screening that detects the presence of ethyl glucuronide (EtG), a direct metabolite of ethanol. EtG can be detected in urine for up to 80 hours after alcohol consumption, making it a sensitive biomarker for recent alcohol exposure.

An amphetamines urine test is a qualitative screening that detects the presence of amphetamine, methamphetamine, MDMA (ecstasy), and related compounds or their metabolites in urine. This test covers a broad class of central nervous system stimulants.

A barbiturates urine test is a qualitative screening that detects the presence of barbiturate compounds or their metabolites in urine. Barbiturates are a class of sedative-hypnotic medications that act on the central nervous system.

A benzodiazepines urine test is a qualitative screening that detects the presence of benzodiazepine compounds or their metabolites in urine. Benzodiazepines are a widely prescribed class of anxiolytic and sedative medications.

A CDT blood test measures carbohydrate-deficient transferrin, a biomarker that indicates chronic heavy alcohol consumption over the preceding weeks. CDT is considered one of the most specific markers for sustained excessive alcohol intake.

A cannabinoids/THC urine test is a qualitative screening that detects the presence of THC metabolites in urine. THC (delta-9-tetrahydrocannabinol) is the primary psychoactive compound in cannabis.

A cocaine urine test is a qualitative screening that detects the presence of cocaine and its primary metabolite benzoylecgonine in urine. Cocaine is a potent central nervous system stimulant derived from the coca plant.

A GHB urine test is a qualitative screening that detects the presence of gamma-hydroxybutyrate (GHB) in urine. GHB is a central nervous system depressant that occurs naturally in the body in trace amounts but may also be used as a recreational substance.

A ketamine urine test is a qualitative screening that detects the presence of ketamine or its metabolites in urine. Ketamine is a dissociative anaesthetic used medically for anaesthesia and pain management, but may also be used as a recreational substance.

An LSD urine test is a qualitative screening that detects the presence of lysergic acid diethylamide (LSD) or its metabolites in urine. LSD is a potent synthetic psychedelic substance that produces effects at very low doses.

A methadone urine test is a qualitative screening that detects the presence of methadone or its metabolites in urine. Methadone is a synthetic opioid used primarily for opioid addiction treatment and chronic pain management.

A methadone metabolite (EDDP) urine test is a qualitative screening that specifically detects EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), the primary metabolite of methadone. Testing for EDDP confirms that methadone has been ingested and metabolised.

A nicotine/cotinine urine test is a qualitative screening that detects the presence of cotinine, the primary metabolite of nicotine, in urine. Cotinine is a reliable biomarker for tobacco and nicotine product use.

An opiates urine test is a qualitative screening that detects the presence of opiate compounds such as morphine, codeine, and their derivatives in urine. Opiates are a class of substances derived from the opium poppy or their semi-synthetic analogues.

The Zuiver PCP urine screening provides reliable, qualitative detection of phencyclidine and its metabolites. This test is suitable for workplace compliance programmes, offering clear results within established cut-off thresholds.

The Zuiver phenibut urine screening provides targeted, qualitative detection of phenibut and its metabolites. This specialised test addresses a gap in standard panels, offering reliable results for extended workplace and clinical screening.

The Zuiver psilocybin urine screening offers specialised, qualitative detection of psilocybin and psilocin. This targeted test extends beyond standard panels to provide accurate results for comprehensive drug screening programmes.

The Zuiver spice urine screening provides reliable, qualitative detection of synthetic cannabinoid metabolites. This targeted test fills a critical gap left by standard cannabis panels, ensuring comprehensive workplace drug screening compliance.